Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2010

View Archived Issues

New inhibitors of TNF-alpha release disclosed

Actelion identifies new antimalarial agents

NeuroSearch describes new monoamine reuptake inhibitors

Ortho-McNeil-Janssen and Addex claim new mGlu2 receptor modulators

FDA grants fast track status to Collegium's tamper-resistant COL-172

Phase III apixaban trial closed early due to clear evidence of efficacy

Dystrophin-based gene therapy evaluated in Duchenne's muscular dystrophy

Dainippon Sumitomo Pharma discloses last year's highlights

MRX-4 improves several symptoms of grass pollen allergy

Trials suggest dasatinib or nilotinib could replace imatinib as first-line CML therapy

ANR-94 is active in rodent models of Parkinson's disease

Cediranib to enter phase II trial in advanced biliary tract cancers

Onset advances COL-177 and COL-179 for skin conditions

Pfizer and Eisai to launch Lyrica in Japan for postherpetic neuralgia

MannKind's Afrezza noninferior to lispro in type 1 diabetes

FDA lifts clinical hold on Repros Therapeutics' Proellex

Human Genome Sciences submits BLA to FDA for Benlysta

Preliminary phase II data released on Surfaxin in children with ARF

Idenix begins phase I/II trial of IDX-320 in chronic hepatitis C

PurGenesis begins phase IIa PUR-0110 trial in distal ulcerative colitis

Cadila Healthcare launches Vaxiflu-S H1N1 vaccine in India

MonoSol Rx and APR Applied Pharma Research expand collaboration

RXi confirms new therapeutic strategy for novel RNAi technology

Health Canada approves Novartis' Menveo vaccine

FDA extends PDUFA date for Acthar sNDA for infantile spasms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...